Indapta Therapeutics Named 2026 Prix Galien USA “Best Startup” Nominee
Recognition places Indapta among an elite group of life sciences startups honored during the awards’ 20th anniversary year HOUSTON & SEATTLE — Indapta Therapeutics, a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies for cancer and autoimmune diseases, has been named a nominee for “Best Startup” in the 2026 Prix Galien USA …